Moderna Tumbles On Report Of Delayed COVID Vaccine Trial
Moderna shares are down 7% following headlines that its virus vaccine trial has been delayed...
A 30,000-patient trial of Moderna’s coronavirus vaccine candidate, expected to start next week, has been delayed, investigators say, while stressing a start later in the month is still possible. https://t.co/w2uzdP6FGU
— STAT (@statnews) July 2, 2020
MRNA back to its lowest since May...
(Click on image to enlarge)
Where's Dr. Fauci to tell us how great it is still?
$MRNA trial delay all but assures they will be left in the dust by the nearly hundred other vaccine candidates IMO
— Quoth the Raven (@QTRResearch) July 2, 2020
Interestingly, this headline hit shortly after WHO's Chief Scientist Soumya Swaminathan said that more analysis was need to understand the efficacy of Remdesivir.
Disclosure: Copyright ©2009-2020 ZeroHedge.com/ABC Media, LTD; All Rights Reserved. Zero Hedge is intended for Mature Audiences. Familiarize yourself with our legal and use policies every time ...
more
There is not another entity that is as fickle or emotion driven as the stock market. So one word of bad news and the picture changes completely. That is the reason that CE types are always spouting the "good news" no matter how little it relates to reality.